Show simple item record

dc.contributor.authorKeller, Josephine Geertsen
dc.contributor.authorPetersen, Kamilla Vandsø
dc.contributor.authorMizielinski, Karol
dc.contributor.authorThiesen, Celine
dc.contributor.authorBjergbæk, Lotte
dc.contributor.authorReguera, Rosa M.
dc.contributor.authorPérez-Pertejo, Yolanda
dc.contributor.authorBalaña-Fouce, Rafael
dc.contributor.authorTrejo, Ángela
dc.contributor.authorMasdeu Margalef, Carme
dc.contributor.authorAlonso Pérez, Concepción Estibaliz ORCID
dc.contributor.authorKnudsen, Birgitta R.
dc.contributor.authorTesauro, Cinzia
dc.date.accessioned2023-06-08T16:09:49Z
dc.date.available2023-06-08T16:09:49Z
dc.date.issued2023-04-27
dc.identifier.citationPharmaceuticals 16(5) : (2023) // Article ID 657es_ES
dc.identifier.issn1424-8247
dc.identifier.urihttp://hdl.handle.net/10810/61332
dc.description.abstractWith the increasing need for effective compounds against cancer or pathogen-borne diseases, the development of new tools to investigate the enzymatic activity of biomarkers is necessary. Among these biomarkers are DNA topoisomerases, which are key enzymes that modify DNA and regulate DNA topology during cellular processes. Over the years, libraries of natural and synthetic small-molecule compounds have been extensively investigated as potential anti-cancer, anti-bacterial, or anti-parasitic drugs targeting topoisomerases. However, the current tools for measuring the potential inhibition of topoisomerase activity are time consuming and not easily adaptable outside specialized laboratories. Here, we present rolling circle amplification-based methods that provide fast and easy readouts for screening of compounds against type 1 topoisomerases. Specific assays for the investigation of the potential inhibition of eukaryotic, viral, or bacterial type 1 topoisomerase activity were developed, using human topoisomerase 1, Leishmania donovani topoisomerase 1, monkeypox virus topoisomerase 1, and Mycobacterium smegmatis topoisomerase 1 as model enzymes. The presented tools proved to be sensitive and directly quantitative, paving the way for new diagnostic and drug screening protocols in research and clinical settings.es_ES
dc.description.sponsorshipThis research was funded in part by the Ministerio de Ciencia e Innovación, Spain (PID2021-122558OB-I00, UE) and by Gobierno Vasco, Universidad del País Vasco (GV, IT1701-22; UPV).es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.relationinfo:eu-repo/grantAgreement/MCIN/PID2021-122558OB-I00es_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjecthuman topoisomerase 1es_ES
dc.subjectMycobacterium smegmatis topoisomerase 1es_ES
dc.subjectLeishmania donovani topoisomerase 1es_ES
dc.subjectmonkeypox virus topoisomerase 1es_ES
dc.subjectenzyme activityes_ES
dc.subjectrolling circle amplificationes_ES
dc.subjectdrug screeninges_ES
dc.titleGel-Free Tools for Quick and Simple Screening of Anti-Topoisomerase 1 Compoundses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.date.updated2023-05-26T13:20:52Z
dc.rights.holder© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).es_ES
dc.relation.publisherversionhttps://www.mdpi.com/1424-8247/16/5/657es_ES
dc.identifier.doi10.3390/ph16050657
dc.departamentoesQuímica orgánica I
dc.departamentoeuKimika organikoa I


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Except where otherwise noted, this item's license is described as © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).